Circulating Tumor Cells as a Promising Tool for Early Detection of Hepatocellular Carcinoma

被引：11

作者：

Salehi, Mahsa ^{[1
]}

Lavasani, Zohre Miri ^{[2
]}

Alikhani, Hani Keshavarz ^{[1
]}

Shokouhian, Bahare ^{[1
]}

Hassan, Moustapha ^{[3
]}

Najimi, Mustapha ^{[4
]}

Vosough, Massoud ^{[1
,3
]}

机构：

[1] Acad Ctr Educ Culture & Res, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Regenerat Med, Tehran 1665666311, Iran

[2] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran 1983969411, Iran

[3] Karolinska Inst, Inst Lab Med, Expt Canc Med, S-17177 Stockholm, Sweden

[4] UCLouvain, Inst Expt & Clin Res IREC, Lab Pediat Hepatol & Cell Therapy, B-1200 Brussels, Belgium

来源：

CELLS | 2023年 / 12卷 / 18期

关键词：

circulating tumor cells; hepatocellular carcinoma; early diagnosis; HCC biomarker; EPITHELIAL-MESENCHYMAL TRANSITION; CLINICAL-SIGNIFICANCE; CANCER PATIENTS; LIQUID BIOPSY; DNA ANALYSIS; EPCAM; LUNG; ENRICHMENT; SEPARATION; BIOMARKER;

D O I：

10.3390/cells12182260

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Liver cancer is a significant contributor to the cancer burden, and its incidence rates have recently increased in almost all countries. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is the second leading cause of cancer-related deaths worldwide. Because of the late diagnosis and lack of efficient therapeutic modality for advanced stages of HCC, the death rate continues to increase by similar to 2-3% per year. Circulating tumor cells (CTCs) are promising tools for early diagnosis, precise prognosis, and follow-up of therapeutic responses. They can be considered to be an innovative biomarker for the early detection of tumors and targeted molecular therapy. In this review, we briefly discuss the novel materials and technologies applied for the practical isolation and detection of CTCs in HCC. Also, the clinical value of CTC detection in HCC is highlighted.

引用

页数：21

共 124 条

[71] Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma [J].